NCT04164199 2026-04-14
Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies
BeOne Medicines
Phase 3 Active not recruiting
Clinical Trials
170 trialsNCT06805305 2026-04-14
DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)
Diakonos Oncology Corporation
Phase 2 Recruiting
NCT07326566 2026-04-14
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
Black Diamond Therapeutics, Inc.
Phase 2 Recruiting
NCT05440786 2026-04-13
CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma
Eli Lilly and Company
Phase 2 Active not recruiting
NCT06012695 2026-04-13
NBM-BMX Administered Orally to Patients With Solid Tumors or Newly Diagnosed Glioblastoma
Novelwise Pharmaceutical Corporation
Phase 1/2 Recruiting
NCT06743126 2026-04-13
SUPRAME
Immatics US, Inc.
Phase 3 Recruiting
NCT03899155 2026-04-01
Pan Tumor Rollover Study
Bristol-Myers Squibb
Phase 2 Recruiting
NCT05765812 2026-03-30
A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
Debiopharm International SA
Phase 1/2 Recruiting
NCT05999994 2026-03-27
CAMPFIRE
Eli Lilly and Company
Phase 2 Recruiting
NCT07492680 2026-03-25
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Bristol-Myers Squibb
Phase 2 Not yet recruiting
NCT06413706 2026-03-24
A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy
Eli Lilly and Company
Phase 2 Active not recruiting
NCT07015242 2026-03-24
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2 Recruiting
NCT03491683 2026-03-19
INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)
Inovio Pharmaceuticals
Phase 1/2 Active not recruiting
NCT03715933 2026-03-18
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
Inhibrx Biosciences, Inc
Phase 1 Recruiting
NCT05109728 2026-03-16
A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.
Novartis
Phase 1 Active not recruiting
NCT06556563 2026-03-13
EF-41
NovoCure Ltd.
Phase 3 Recruiting
NCT05417594 2026-03-12
CERTIS1
AstraZeneca
Phase 1/2 Recruiting
NCT07297212 2026-03-12
A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma
BioNTech SE
Phase 2 Recruiting
NCT07195591 2026-03-04
BRIDGES
GT Medical Technologies, Inc.
Phase 3 Recruiting
NCT07310784 2026-03-03
A Phase II Trial of LM103 in Advanced Melanoma
Suzhou BlueHorse Therapeutics Co., Ltd.
Phase 2 Recruiting
NCT04238819 2026-03-02
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma
Eli Lilly and Company
Phase 1/2 Completed
NCT06346067 2026-02-27
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)
Erasca, Inc.
Phase 3 Active not recruiting
NCT04478279 2026-02-09
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
Sapience Therapeutics
Phase 1/2 Active not recruiting
NCT05739942 2026-02-03
Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma
Novartis
Phase 1 Active not recruiting
NCT04752813 2026-01-26
A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)
BPGbio
Phase 2 Active not recruiting
NCT07365280 2026-01-26
Neoantigen-Pulsed Autologous Dendritic Cell Vaccine Combined With Temozolomide for Newly Diagnosed Glioblastoma
ZSky Biotech Inc
Phase 2 Not yet recruiting
NCT06105619 2026-01-20
A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN).
Beijing Pearl Biotechnology Limited Liability Company
Phase 2/3 Active not recruiting
NCT07349693 2026-01-20
Cerebraca-02/3
Everfront Biotech Co., Ltd.
Phase 2/3 Not yet recruiting
NCT06703398 2025-12-23
MIZAR-003
Shanghai Juncell Therapeutics
Phase 2 Recruiting
NCT06931626 2025-11-12
Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer
Nerviano Medical Sciences
Phase 1 Recruiting
NCT05902169 2025-11-10
SONOBIRD
CarThera
Phase 3 Active not recruiting
NCT04373785 2025-10-21
NG101m Adjuvant Therapy in Glioblastoma Patients
NeuGATE Theranostics
Phase 1/2 Not yet recruiting
NCT05429502 2025-10-10
Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors
Novartis
Phase 1 Terminated
NCT04337177 2025-09-23
Flavored, Oral Irinotecan VAL-413 (OrotecanĀ®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors
Valent Technologies, LLC
Phase 1 Recruiting
NCT04919226 2025-09-10
COMPOSE
ITM Solucin GmbH
Phase 3 Active not recruiting
NCT06624644 2025-09-10
A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
Linnaeus Therapeutics, Inc.
Phase 2/3 Recruiting
NCT01107522 2025-09-09
Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With TemodarĀ® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With TemodarĀ® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas
Tactical Therapeutics, Inc.
Phase 1 Unknown
NCT04587830 2025-08-26
GBM
Polaris Group
Phase 2 Active not recruiting
NCT04910022 2025-08-19
Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma
Nerviano Medical Sciences
Phase 1/2 Active not recruiting
NCT07120984 2025-08-13
IMAGLIO
Philogen S.p.A.
Phase 2 Not yet recruiting
NCT04388475 2025-08-12
Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma
Oblato, Inc.
Phase 2 Completed
NCT04239092 2025-07-17
9-ING-41 in Pediatric Patients With Refractory Malignancies.
Actuate Therapeutics Inc.
Phase 1 Terminated
NCT04400188 2025-06-29
A Study of Fluzoparib (SHR-3162) and Temozolomide With or Without SHR-1316 in Treating Patients With Replapsed Small Cell Lung Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2 Completed
NCT04121455 2025-06-25
GLORIA
TME Pharma AG
Phase 1/2 Active not recruiting
NCT05879367 2025-06-25
Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma
Orbus Therapeutics, Inc.
Phase 1 Recruiting
NCT02667587 2025-06-18
CheckMate548
Bristol-Myers Squibb
Phase 3 Completed
NCT02655601 2025-06-08
BMX-HGG
BioMimetix JV, LLC
Phase 1/2 Completed
NCT04566380 2025-06-03
ONO-4538 Phase II Rollover Study (ONO-4538-98)
Ono Pharmaceutical Co. Ltd
Phase 2 Recruiting
NCT03782415 2025-05-21
Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent Glioblastoma
MediciNova
Phase 1/2 Completed
NCT05769660 2025-03-10
A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Temozolomide in Patients with Recurrent or Progressive Glioblastoma Multiforme (GBM)
BeyondBio Inc.
Phase 1 Recruiting